Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
Study sponsor: Definium Therapeutics US, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-11-06Actual
Enrollment · participants53Actual
Source updated2026-02-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.